CROs offering Phase IV / Post-Marketing with Antibody-Drug Conjugate (ADC)
8 published
8 published CROs match Phase IV / Post-Marketing and Antibody-Drug Conjugate (ADC).
Locations in this set include United States, Canada, China, United Kingdom, 30 countries, and 30+ countries.
Capabilities that show up most often in this set: Biostatistics & Statistical Programming, Phase I Clinical Trials, Phase II Clinical Trials, Phase III Clinical Trials, and Data Management & eClinical.
Matching companies
AllucentAllucent is a full-service CRO specializing in clinical development solutions for small and mid-sized biotech companies.
CelerionGlobal CRO specializing in early-phase clinical research and bioanalytical sciences with 650+ beds across 30 countries and 50+ years of experience.
CertaraCertara transforms drug development with proprietary biosimulation software, predictive modeling, and AI-driven services spanning discovery through commercialization. Serving 2,400+ biopharmaceutical companies and regulatory agencies across 70 countries, Certara's model-informed drug development (MIDD) platform accelerates clinical and regulatory decision-making.
PharmaronPremier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
Syneos HealthGlobal CRO with 26,000+ employees offering integrated clinical development, regulatory affairs, and commercialization services. Helped develop or commercialize 96% of FDA-approved oncology drugs and 93% of EMA-authorized oncology products in the last five years.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
Worldwide Clinical TrialsFull-service global CRO with 30+ years of therapeutic expertise, delivering personalized clinical trial support across rare disease, cardiovascular, cell & gene therapy, oncology, and neuroscience.
WuXi AppTecGlobal CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.
Markdown mirror: /explore/phase-4-post-marketing/antibody-drug-conjugate.md